GH Research PLC - Ordinary Shares (GHRS)

GH Research stated that the FDA has cleared GH001 for a clinical investigation in the U.S.

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

GH Research Q3 2025 results show a slight EPS beat. The biotech firm is focused on resolving the FDA clinical hold for its GH001 treatment for depression.

GH Research's GH001 shows strong Phase 2 results for treatment-resistant depression, with FDA issues nearly resolved and $1.9 billion U.S. potential.

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Let's explore the current happenings on the US markets on Thursday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Discover the stocks with unexpected trading volume in today's session on the US markets.

In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.

GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.

Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches.

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.